We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App





New One-Minute COVID-19 Test Detects Antibodies from Single Drop of Blood

By LabMedica International staff writers
Posted on 30 May 2020
A one-minute test for antibodies to SARS-CoV-2 is currently being developed based on an innovative testing technology that detects antibodies within one minute from a single drop of blood.

The test is being developed on bioLytical Laboratories Inc.’s (Richmond, BC, Canada) proprietary INSTI platform. More...
bioLytical will receive advisory services and funding from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) to develop the one-minute test for antibodies to SARS-CoV-2.

INSTI is made in Canada and known for its fast, easy-to-use, and accurate serological tests. As an antibody test, an INSTI test for SARS-CoV-2 can be an important part of the testing strategy in Canada and around the world. By detecting antibodies to COVID-19 in a single drop of blood, INSTI does not require additional materials such as swabs. Along with the test device, all materials required to perform the test are provided together in one small pouch; leading this testing platform to become known as “a lab in a pouch.”

The INSTI SARS-CoV-2 test development project is funded by NRC IRAP and aims to accelerate research and development for solutions to address COVID-19 related gaps and challenges identified by health experts.

Related Links:
bioLytical Laboratories Inc.


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Automated Clinical Chemistry Analyzer
Envoy 500+
New
All-in-One Molecular System
AIO M160
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.